ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Catalent is buying San Diego-based Pharmatek Laboratories for an undisclosed amount. The purchase will add early-stage dosage-form drug development capabilities, analytical services, and clinical-scale manufacturing to Catalent’s drug delivery and formulation business. In particular, Catalent will gain spray-drying technology and expand its ability to handle highly potent compounds. Pharmatek works on oral, injectable, and topical products for more than 100 customers, the companies say.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter